Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Table 2 Adjusted efficacy outcome measures in patients with or without enthesitis at baseline

Outcome measures	Week	With enthesitis at baseline			Without enthesitis at baseline
		Secukinumab		Placebo (N = 163)	Secukinumab		Placebo (N = 72)
		300 mg (N = 144)	150 mg (N = 159)	Placebo (N = 163)	300 mg (N = 95)	150 mg (N = 79)	Placebo (N = 72)
ACR20^a,b	16	51.6	44.3	19.5	48.8	60.4	13.8
ACR20^a,b	104	55.2	59.1	–	57.6	59.8	–
ACR50^a,b	16	31.4	21.0	7.5	32.6	32.9	4.1
ACR50^a,b	104	43.4	25.7	–	43.5	28.9	–
ACR70^a,b	16	20.5	10.7	2.9	23.4	18.5	1.4
ACR70^a,b	104	26.7	17.0	–	32.8	18.9	–
PASI 90^a,c	16	66.5	51.8	13.1	56.4	48.9	10.8
PASI 90^a,c	104	46.2	34.9	–	52.5	24.8	–
PASI 75^a,c	16	82.3	62.0	10.6	68.1	59.8	7.3
PASI 75^a,c	104	88.5	87.4	–	95.5	80.1	–
HAQ-DI^d	16	− 0.5	− 0.3	− 0.2	− 0.4	− 0.5	− 0.2
HAQ-DI^d	104	− 0.4	− 0.3	–	− 0.5	− 0.5	–
SF-36 PCS^d	16	6.1	3.5	2.3	6.1	7.0	2.0
SF-36 PCS^d	104	6.9	4.0	–	6.3	6.0	–
DAS28-CRP^d	16	− 1.4	− 1.0	− 0.5	− 1.3	− 1.5	− 0.4
DAS28-CRP^d	104	− 1.7	− 1.5	–	− 1.9	− 1.7	–

Logistic regression (for binary variables) or ANCOVA (for continuous variables) were performed as a function of the patient characteristics at baseline (treatment group, enthesitis status, gender, DAS28-CRP, HAQ-DI, TNFi-status), and the interaction between treatment groups and enthesitis status
ACR American College of Rheumatology, DAS28-CRP; 28-Joint Disease Activity Score count using C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, LS least square, n number of evaluable patients, N total number of patients, PASI Psoriasis Area and Severity Index, SF-36 PCS Short Form 36 Physical Component Summary score
^aResponse, %
^bAt week 16/104, n = 144/132 (secukinumab 300 mg), 159/145 (secukinumab 150 mg), and 163 (placebo) with enthesitis and n = 95/91 (secukinumab 300 mg), 79/70 (secukinumab 150 mg), and 72 (placebo) without enthesitis at baseline
^cAt week 16/104, n = 66/56 (secukinumab 300 mg), 82/62 (secukinumab 150 mg), and 63 (placebo) with enthesitis and n = 38/34 (secukinumab 300 mg), 46/36 (secukinumab 150 mg), and 30 (placebo) without enthesitis at baseline (psoriasis subset)
^dLS mean change from baseline

ISSN: 1478-6362